NSTEMI: RISK STRATIFICATION AND MANAGEMENT Kshitij S. Mavade Defination
Features that help differentiate ACS from stable angina are (1) onset of symptoms at rest (or with minimal exertion) and lasting longer than 10 minutes unless treated promptly; (2) severe, oppressive pressure or chest discomfort; and (3) an accelerating pattern of symptoms that develop more frequently, occur with greater severity, or awaken the patient from sleep Clinical Assessment
Physical examination / clinical history Electrocardiogram Cardiac biomarkers Risk stratification Further investigations History
NSTE-ACS most commonly presents as a pressure-type chest pain that typically occurs at rest or with minimal exertion lasting 10 minutes Relatively uncommon in men <40 yr. and women < 50 yr Previous history of coronary heart disease(CHD)
Presence of traditional risk factors for CHD. Atypical manifestations :anginal equivalents- more prevalent in women, older adults, patients with DM2, CKD or Dementia. Unexplained new-onset or increased exertional dyspnea is the most common angina equivalent
Secondary NSTE ACS :cause is extrinsic to coronaries Increase in myocardial O2 demand: fever, tachycardia, hypertensive emergencies Decrease in supply: hypotension, anemia Pysical examianation
May be normal Audible S3 and/or S4 Hypotension, pale cool skin, cardiogenic shock To r/ o other non coronary cardiac cause/noncardiac cause ECG A 12-lead ECG should be performed and interpreted within 10 minutes of the patients arrival at an emergency facility to assess for cardiac ischemia
or injury. Changes include ST depression, transient ST-elevation, or new T-wave inversion Significant changes: 0.05mV ST Depression compare to recent ECG (In PURSUIT trial 30 day mortality was 5.1% in patient with ST depression compared to 2.1% in patient without ST depression)
Deep T wave inversion of >0.2mV Transient ST elevation lasting for <20 min A normal ECG does not exclude ACS and occurs in 1% to 6% of such patients. A normal ECG may also be associated with left circumflex or right coronary artery occlusions, which can be electrically silent.
posterior electrocardiographic leads [V7 to V9] may be helpful. Rightsided leads (V3R to V4R) Left ventricular (LV) hypertrophy, bundlebranch blocks with repolarization abnormalities, and ventricular pacing may mask signs of ischemia/injury. ECG should be repeated (e.g., at 15- to 30-minute intervals during them
first hour), especially if symptoms recur biomarkers Cardiac troponins are the most sensitive and specific biomarkers for NSTEACS. Even minor elevation in cTn levels associated with poor outcome.
Diagnosis of acute MI requires an elevation in cTnI or cTnT above the 99th percentile of the normal range for the specific assay used, a typical temporal rise and decline when serial samples are tested, and a clinical picture consistent with ACS. A negative cardiac troponin obtained with more sensitive cardiac troponin assays on admission confers a >95% negative predictive value for MI compared with high-sensitivity assays that confer a negative predictive value 99%
Newer high-sensitivity assays can, exclude myocardial necrosis if two values measured 3 hours apart are both normal. The fourth-generation cTn assays are less sensitive than the so-called high-sensitivity assays, and two negative cTn assays at least 6 to 9 hours apart are needed to exclude MI. Causes of troponin elevation other than ACS Pulmonary embolus
myocarditis Cardiac contusion Congestive heart failure Chemiotherapy (adiramycin, 5-flurouracil) Cardioversion or RFA Septic shock Extreme endurance athletics Renal failure Pro-BNP & NT-Pro BNP No diagnostic, but prognostic significance.
rise in proportion to the degree of ventricular distention and correlate with the risk for adverse events In patients with NSTE-ACS, a baseline BNP measured on average 40 hours after the onset of symptoms correlated strongly with risk for death, heart failure, and MI through 10 months in a graded fashion.
CRP & other biomarkers C-reactive protein (CRP) is a marker of inflammation that is elevated following ACS, and persistently elevated levels after discharge are associated with increased long-term cardiovascular risk. CRP provides less prognostic information than cTn & Pro BNP, routine CRP measurement after ACS is not recommended.
Others , if elevated shows increased chances of CV events in both short and long terms e.g. Blood sugar level HbA1c Markers for renal dysfunctions- cystatin c, serum creatinine Emerging biomarkers Markers that predict death and/ ischemic events Growth differentiation factor 15 (GDF 15) Heart-type fatty acid binding protein (H-FABP) myeloperoxidase
Pregnancy associated plasma protein A (PAPP-A)- expressed in eroded and ruptured plaque Placental growth factor Secretory phospholipase A2 Interleukin-6 (IL-6) Chemokine ligand-5 & ligand 18 Markers that predict heart failure Midregional proadrenomedullin neopterin osteoprotegrin
ECHO useful in the assessment of left ventricular systolic and diastolic function left atrial dilation, functional mitral regurgitation, tricuspid annular plane systolic excursion, diastolic dysfunction, ventricular mechanical dyssynchrony, and ultrasound lung comets
Each of which have been associated with adverse prognosis Invasive imaging The culprit lesion in NSTE-ACS typically exhibits an eccentric stenosis with scalloped or overhanging edges and a narrow neck. CAG findings in NSTE ACS %
Multivessel with LMCA 10% TVD 35% DVD 20%
SVD 20% Normal coronaries 15% 85 %
Normal coronaries- more frequently in women and nonwhites individuals. In such patients, NSTE-ACS, if present, may be related to microvascular coronary obstruction, endothelial dysfunction, or coronary artery spasm and is generally associated with a more favourable prognosis. Objectives of stratification
Can We Identify Patients At Low, Intermediate And High Risk Of Short Term And Long Term Macce? Will It Help To Guide Treatment For Better Outcome? Acute coronary syndromes: Prognostic spectrum
Unstable angina New onset exertional angina Progressive angina Rest pain without EKG changes Rest pain with EKG changes
Rest pain troponin+ Non ST elevation MI (NSTEMI) Acute ST segment elevation MI Lea st RISK Coronary occlusion & short term death
Great est Clinical Indicators of Increased Risk in UA/NSTEMI History Clinical Presentation Advanced age (> 70 yr) Braunwald class II or III (acute or
Left ventricular dysfunction Braunwald class B (secondary unstable angina) Heart failure/hypotension Multiple episodes of pain within 24 hr Cardiac Markers Increased troponin T or I or creatine kinase-MB Increased C-reactive protein or white blood cell count Increased B-type natriuretic peptide Elevated creatinine
Elevated glucose or hemoglobin A1C The TIMI unstable angina risk score
7 possible risk factors: Age >= 65 years Prior known CAD >= 3 coronary risk factors ( HTN, Hchol, FH, DM, current smoker) Aspirin use within 7 days ST segment deviation >= 2 episodes of angina within 24 hours Abnormal cardiac markers (MB or T) Low risk = 0-2 risk factors Intermediate risk = 4-3 risk
factors High risk = 5-7 risk factors Antman EM et al: JAMA 2000;284:83542
The TIMI risk score has been validated internally within the TIMI 11B trial and in 2 separate cohorts of patients from the ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in NonQ-Wave Coronary Event) trial The TIMI risk index is useful in predicting 30-day and 1-year mortality in patients with NSTE-ACS The c-statistic of the TIMI score in the original trial was0.65. Risk Scores for Patients with Chest Pain: Evaluation in the EmergencyDepartment B.E. Backus1,*, A.J. Six2, J.H. Kelder3, W.B. Gibler4, F.L. Moll1 and P.A. Doevendans1 Current Cardiology Reviews, 2011, 7, 2-8
Sex Male Female Worst CCS-class in previous 6 weeks No angina or CCS I/II CCS III/IV Signs of heart failure ST-depression on presenting ECG 1 0 0
2 2 1 Eur Heart J (May 2005) 26 (9):865-872. possible score ranging from 1 to 18. The PURSUIT score predicts the risk of death
or death/MI at 30 days after admission. According to the PURSUIT score ACS patients are divided into low, intermediate and high risk patients, with suggested therapies of early discharge, watchful waiting and aggressive antiplatelet / early invasive strategies respectively Risk Scores for Patients with Chest Pain: Evaluation in the EmergencyDepartment B.E. Backus1,*, A.J. Six2, J.H. Kelder3, W.B. Gibler4, F.L. Moll1 and P.A. Doevendans1 Current Cardiology Reviews, 2011, 7, 2-8 GRACE(0258) Age (years)
The GRACE tool was developed from 11,389 patients in GRACE and validated in subsequent GRACE and GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) IIb cohorts determine all-cause mortality from hospital discharge to 6 months
possible score ranging from 1 to 372 Event rates increased significantly with increasing GRACE-scores, ranging from 0.2% to 52% chance of inhospital death The investigators did not divide patients into different risk categories. The c-statistic of the GRACE score in the original database was 0.83. Risk Scores for Patients with Chest Pain: Evaluation in the EmergencyDepartment B.E. Backus1,*, A.J. Six2, J.H. Kelder3, W.B. Gibler4, F.L. Moll1 and P.A. Doevendans1
Current Cardiology Reviews, 2011, 7, 2-8 The FRISC score (2004) is based on the FRISC (Fast Revascularisation in Instability in
Coronary disease) II trial. c-statistic of the FRISC score for the prediction of death was 0.77 and for death/MI 0.70. low, intermediate and high risk, based on the FRISC scores of 0-2, 3-4 and 5-7. In one study conducted over 1200 patients, the high risk group mortality reduced from 15.4 5.2%, while the composite endpoint of death and MI was reduced in both intermediate and high risk groups. The FRISC score is the only risk score that focussed on the treatment effect of early invasive strategies in ACS. Investigators recommended early invasive strategies for patients with a FRISC score 3. Risk Scores for Patients with Chest Pain: Evaluation in the EmergencyDepartment B.E. Backus1,*, A.J. Six2, J.H. Kelder3, W.B. Gibler4, F.L. Moll1 and P.A. Doevendans1 Current Cardiology Reviews, 2011, 7, 2-8
Heart scoring History ECG Age Risk factor Troponin Highly suspicious
2 Moderately suspicious 1 Slightly suspicious 0 Significant ST depression
2 Non specific repolarization disturbance 1 normal 0 65 2
46-64 1 45 0 3 risk facor or known atherosclerotic disease 2
1-2 risk factors 1 No risk fctor known 0 3x normal limit 2 1-3x normal limit
1 normal limit 0 Low risk 0-3 0.9%
Intermediate risk 4-6 12% High risk 7-10 65%
the HEART risk score (2008) was developed for chest pain patients presenting to the ED Investigator assessed endpoint of MI, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG) ordeath within 6 weeks after presentation. The c-statistic was 0.90, indicating good toexcellent
discriminative power. The HEART score divides patients into low (0-3), intermediate (4-6) or high risk groups (7-10), with mean risks of an event of 0.9%, 12% and 65%, respectively Risk Scores for Patients with Chest Pain: Evaluation in the EmergencyDepartment B.E. Backus1,*, A.J. Six2, J.H. Kelder3, W.B. Gibler4, F.L. Moll1 and P.A. Doevendans1 Current Cardiology Reviews, 2011, 7, 2-8 TIMI, PURSUIT, AND GRACE RISK SCORES: SUSTAINED PROGNOSTIC VALUE AND INTERACTION WITH REVASCULARIZATION IN NSTEACS
Pedro de Arajo Gonalves, Jorge Ferreira, Carlos Aguiar and Ricardo Seabra-Gomes Eur Heart J (May 2005) 26 (9):865872. Interaction between the admission score and the prognostic impact of myocardial revascularization performed during initial hospital stay. Eur Heart J (May 2005) 26 (9):865872. Comparison of the predictive accuracy of the risk scores
30 days 1 year P-value P-value PURSUIT vs. TIMI
0.064 0.288 0.044 0.319 GRACE vs. PURSUIT 0.057
0.332 0.086 0.04 GRACE vs. TIMI 0.121 0.054
0.130 0.004 Eur Heart J (May 2005) 26 (9):865-872. Conclusions RSs developed from Databases of clinical trials (PURSUIT and TIMI) or
Registries (GRACE) At 30 days the risk stratification by all 3 scores for patients with NSTEACS has fair to good discriminatory accuracy in predicting major adverse cardiac events at both 30 days and 1 year. The
GRACE RS was the best for predicting the risk of death or MI at 1 year after admission. Eur Heart J (May 2005) 26 (9):865-872. Risk Scores for Patients with Chest Pain: Evaluation in the EmergencyDepartment B.E. Backus1,*, A.J. Six2, J.H. Kelder3, W.B. Gibler4, F.L. Moll1 and P.A. Doevendans1 Current Cardiology Reviews, 2011, 7, 2-8 A prospective validation of the HEART score for chest pain patients at the emergency department B.E. Backus et al
International Journal of Cardiology 168 (2013) 21532158 Methods: A total of 2440 unselected patients presented with chest pain at the cardiac emergency department of ten participating hospitals in The Netherlands. The HEART score was assessed as soon as the first lab results and ECG were obtained. Primary endpoint was the
occurrence of major adverse cardiac events (MACE) within 6 weeks. Conclusion: The HEART score provides the clinician with a quick and reliable predictor of outcome, without computer-required calculating. Low HEART scores (03), exclude short-term MACE with >98% certainty. In these patients one
might consider reserved policies. In patients with high HEART scores (710) the high risk of MACE may indicate more aggressive policies. 2014 AHA/ACC GUIDELINE FOR THE MANAGEMENT OF PATIENTS WITH NONST-ELEVATION ACUTE CORONARY SYNDROMES: EXECUTIVE SUMMARY A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Circulation. published online September 23, 2014 INITIAL EVALUATION AND MANAGEMENT Emergency Department or Outpatient Facility Presentation Patients with suspected ACS and high-risk features such as continuing chest pain, severe dyspnea, syncope/presyncope, or palpitations should be referred
immediately to the ED and transported by EMS when available. (Class I; Level of Evidence C) Prognosis: Early Risk Stratification Perform rapid determination of likelihood of ACS, including a 12-lead ECG within 10 min of arrival at an emergency facility, in patients whose symptoms suggest ACS (Class I) Perform serial ECGs at 15- to 30-min intervals during the first hour in symptomatic patients with initial
nondiagnostic ECG (Class I) Measure cardiac troponin (cTnI or cTnT) in all patients with symptoms consistent with ACS (Class I) Measure serial cardiac troponin I or T at presentation and 36 h after symptom onset Prognosis: Early Risk Stratification Use risk scores to assess prognosis in patients with NSTE-ACS (Class I) Risk-stratification models can be useful in management (Class IIa)
Continuous monitoring with 12-lead ECG may be a reasonable alternative with initial non-diagnostic ECG in patients at intermediate/high risk for ACS (Class IIb) BNP or NTpro-BNP may be considered to assess risk in patients with suspected ACS (Class IIb) Biomarkers: Diagnosis
Measure cardiac-specific troponin (troponin I or T) at presentation and 36 h after symptom onset in all patients with suspected ACS to identify pattern of values (Class I) Obtain additional troponin levels beyond 6 h in patients with initial normal serial troponins with ECG changes and/or intermediate/high risk clinical features (Class I) With contemporary troponin assays, CK-MB and myoglobin are not useful for diagnosis of ACS (Class III)
Discharge From the ED or Chest Pain Unit Observe patients with symptoms consistent with ACS without objective evidence of myocardial ischemia (non-ischemic initial ECG and normal cardiac troponin) in a chest pain unit or telemetry unit with serial ECGs and cardiac troponin at 3- to 6-hour intervals
(Class IIa) Give low-risk patients who are referred for outpatient testing daily aspirin, short-acting NTG, and other medication if appropriate (e.g., beta blockers), with instructions about activity level and clinician follow-up (Class IIa) EARLY HOSPITAL CARE STANDARD MEDICAL THERAPIES
Oxygen Administer supplemental oxygen only with oxygen saturation <90%, respiratory distress, or other high-risk features for hypoxemia (Class I) Nitrates
Administer sublingual NTG every 5 min 3 for continuing ischemic pain and then assess need for IV NTG (Class I) Administer IV NTG for persistent ischemia, HF, or hypertension (Class I) Nitrates are contraindicated with recent use of a phosphodiesterase inhibitor (Class III)
Analgesic therapy IV morphine may be reasonable for continued ischemic chest pain despite maximally tolerated anti-ischemic medications (Class IIb) NSAIDs (except aspirin) should not be initiated and should be discontinued during hospitalization for NSTE-ACS because of the increased risk of MACE
associated with their use (Class III) Beta-adrenergic blockers Initiate oral beta blockers within the first 24 h in the absence of HF, low-output state, risk for cardiogenic shock, or other contraindications to beta blockade (Class I)
Use of sustained-release metoprolol succinate, carvedilol, or bisoprolol is recommended for beta-blocker therapy with concomitant NSTE-ACS, stabilized HF, and reduced systolic function (Class I) IV beta blockers are potentially harmful when risk factors for shock are present (Class III) CCBs
Administer initial therapy with non-DHP CCBs with recurrent ischemia and contraindications to beta blockers in the absence of LV dysfunction, increased risk for cardiogenic shock, PR interval >0.24 s, or 2ndor 3rd-degree AV block without a cardiac pacemaker (Class I) Administer oral non-DHP CCBs with recurrent ischemia after use of beta-blocker and nitrates in the absence of contraindications (Class I)
CCBs are recommended for ischemic symptoms when beta-blockers are not successful, are contraindicated, or cause unacceptable side effects (Class I) Immediate-release nifedipine is contraindicated in the absence of a beta-blocker (Class III) Inhibitors of Renin-AngiotensinAldosterone System ACE inhibitors should be started and
continued indefinitely in all patients with LVEF < 0.40 and in those with hypertension, DM, or stable CKD, unless contraindicated (Class I) ARB are recommended in patients with HF or MI with LVEF < 0.40 who are ACE inhibitor intolerant (Class I) INITIAL PARENTERAL ANTICOAGULANT THERAPY IN PATIENTS WITH DEFINITE NSTE-ACS
Aspirin Nonenteric-coated aspirin (162 mg325 mg) to all patients promptly after presentation and maintenance dose (81 mg/d162 mg/d) continued indefinitely (Class I) P2Y12 inhibitors
In patients with NSTE-ACS who are unable to take aspirin because of hypersensitivity or major gastrointestinal intolerance, a loading dose of clopidogrel followed by a daily. maintenance dose should be administeredP2Y12 inhibitor in addition to aspirin should be administered for up to 12 mo to all patients with NSTE-ACS without contraindications who are treated with either an early invasive or ischemia-guided strategy (Class I) Clopidogrel
300-mg or 600-mg loading dose, then 75 mg QD Ticagrelor 180-mg loading dose, then 90 mg BID P2Y12 inhibitor therapy continued for at least 12 mo in postPCI patients treated with coronary stents (Class I) Ticagrelor in preference to clopidogrel for patients treated
GP IIb/IIIa inhibitors GP IIb/IIIa inhibitor [Eptifibatide (Integrilin) or tirofiban (Aggrastat)] in patients treated with an early invasive strategy and dual anti-platelet therapy (DAPT) with intermediate/high-risk features (e.g., positive troponin) (Class IIb) Parenteral anticoagulant
and fibrinolytic therapy SC enoxaparin for duration of hospitalization or until PCI is performed (Class I)
1 mg/kg SC Q12H (reduce dose to 1 mg/kg/d SC in patients with CrCl <30 mL/min) Initial IV loading dose 30 mg Bivalirudin until diagnostic angiography or PCI is performed in patients with early invasive strategy only (Class I) Fondaparinux 2.5 mg SC QD for the duration of hospitalization or until PCI is performed (Class I) IV UFH for 48 h or until PCI is performed (Class I) Initial loading dose 60 IU/kg (max 4,000 IU) with initial infusion 12 IU/kg/h (max 1,000 IU/h) Adjusted to therapeutic aPTT range IV fibrinolytic treatment not recommended in patients
Summary of Recommendations for Initial Antiplatelet/Anticoagulant Therapy in Patients With Definite or Likely NSTE-ACS and PCI ISCHEMIA-GUIDED STRATEGY VERSUS EARLY INVASIVE STRATEGIES EARLY INVASIVE AND ISCHEMIA-GUIDED STRATEGIES
Risk Stratification Before Discharge for Patients With an Ischemia-Guided Strategy of NSTE-ACS: Recommendations CLASS I Noninvasive stress testing is recommended in low- and intermediaterisk patients who have been free of ischemia at rest or with low-level activity for a minimum of 12 to 24 hours. Treadmill exercise testing is useful in patients able to exercisem in whom the ECG is free of resting ST changes that may interfere with interpretation.
Stress testing with an imaging modality should be used in patients who are able to exercise but have ST changes on resting ECG that may interfere with interpretation. In patients undergoing a low-level exercise test, an imaging modality can add prognostic information.
Pharmacological stress testing with imaging is recommended when physical limitations preclude adequate exercise stress. A noninvasive imaging test is recommended to evaluate LV function in patients with definite ACS. PCIGeneral Considerations: Recommendation CLASS 2B A strategy of multivessel PCI, in contrast to culprit lesion only PCI, may be
reasonable in patients undergoing coronary revascularization as part of treatment for NSTEACS PCI-Oral and Intravenous Antiplatelet Agents: Recommendations CLASS I Patients already taking daily aspirin before PCI should take 81 mg to 325 mg nonenteric-coated aspirin before PCI. Patients not on aspirin therapy should be given nonenteric coated aspirin 325 mg
as soon as possible before PCI. After PCI, aspirin should be continued indefinitely at a dose of 81 mg to 325 mg daily. CLASS 1 A loading dose of a P2Y12 receptor inhibitor should be given before the procedure in patients undergoing PCI with stenting Options include: a. Clopidogrel: 600 mg b. Prasugrel: 60 mg c. Ticagrelol: 180 mg
In patients with NSTE-ACS and high-risk features (e.g., elevated troponin) not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI ( In patients receiving a stent (bare-metal stent or drugeluting stent [DES]) during PCI for NSTE-ACS, P2Y12 inhibitor therapy
should be given for at least 12 months. Options include: a. Clopidogrel: 75 mg daily b. Prasugrel: 10 mg daily c. Ticagrelol: 90 mg twice daily CLASS IIa It is reasonable to choose ticagrelor over clopidogrel for P2Y12 inhibition treatment in patients with NSTEACStreated with an early invasive strategy and/or coronary stenting. It is reasonable to choose prasugrel over clopidogrel for P2Y12 treatment in patients with NSTE-ACS who undergo
PCI who are not at high risk of bleeding complications. In patients with NSTE-ACS and high-risk features (e.g., elevated troponin) treated with UFH and adequately pretreated with clopidogrel, it is reasonable to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-bolus dose tirofiban) at the time of PCI After PCI, it is reasonable to use 81 mg per day of aspirin in preference to higher
maintenance doses. If the risk of morbidity from bleeding outweighs the anticipated benefit of a recommended duration of P2Y12 inhibitor therapy after stent implantation, earlier discontinuation (e.g., <12 months) of P2Y12 inhibitor therapy is reasonable. CLASS IIb Continuation of DAPT beyond 12 months may be considered in patients undergoing stent implantation. CLASS III: HARM
Prasugrel should not be administered to patients with a prior history of stroke or transient ischemic attack. Timing of Urgent CABG in Patients With NSTEACS in Relation to Use of Antiplatelet Agents: Recommendations CLASS I Nonenteric-coated aspirin (81 mg to 325 mg daily) should be administered preoperatively to patients undergoing CABG. In patients referred for elective CABG, clopidogrel and ticagrelor should be discontinued for at least
5 days before surgery (Level of Evidence: B) and prasugrel for at least 7 days before surgery In patients referred for urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 hours to reduce major bleeding In patients referred for CABG, short-acting intravenous GPnIIb/IIIa inhibitors (eptifibatide or tirofiban) should be discontinued for at least 2 to 4 hours before surgery and abciximab for at least 12 hours before to limit blood loss and transfusion CLASS 2B
In patients referred for urgent CABG, it may be reasonable to perform surgery less than 5 days after clopidogrel or ticagrelor has been discontinued and less than 7 days after prasugrel has been discontinued LATE HOSPITAL CARE, HOSPITAL DISCHARGE, AND POSTHOSPITAL DISCHARGE CARE
CLASS I Medications required in the hospital to control ischemia should be continued after hospital discharge in patients with NSTE-ACS who do not undergo coronary revascularization, patients with incomplete or unsuccessful revascularization and patients with recurrent symptoms after revascularization. Titration of the doses may be required. All patients who are postNSTE-ACS should be given sublingual or spray nitroglycerin with verbal and written instructions for its use.
Before hospital discharge, patients with NSTE-ACS should be informed about symptoms of worsening myocardial ischemia and MI and should be given verbal and written instructions about how and when to seek emergency care for such symptoms. Before hospital discharge, patients who are post NSTE-ACS and/or designated responsible caregivers should be provided with easily
understood and culturally sensitive verbal and written instructions about medication type, purpose, dose, frequency, side effects, and duration of use. For patients who are postNSTE-ACS and have initial angina lasting more than 1 minute, nitroglycerin (1
dose sublingual or spray) is recommended if angina does not subside within 3 to 5 minutes; call 9-1-1 immediately to access emergency medical services. If the pattern or severity of angina changes, suggesting worsening myocardial ischemia (e.g., pain is more frequent or severe or is precipitated by less effort or occurs at rest), patients should contact their clinician without delay to assess the need for additional treatment or testing. Before discharge, patients should be educated about modification of cardiovascular risk factors Late Hospital and Posthospital Oral Antiplatelet
Therapy: Recommendations CLASS I Aspirin should be continued indefinitely. The maintenance dose should be 81 mg daily in patients treated with ticagrelor and 81 mg to 325 mg daily in all other patients. In addition to aspirin, a P2Y12 inhibitor (either clopidogrel or ticagrelor) should be continued for up to 12 months in all patients with NSTE-ACS without contraindications who are treated with an ischemia-guided strategy.
Options include: Clopidogrel: 75mg daily Ticagrelor: 90 mg twice daily In patients receiving a stent (bare-metal stent or DES) during PCI for NSTE-ACS,
P2Y12 inhibitor therapy should be given for at least 12 months . Options include: Clopidogrel: 75 mg daily Prasugrel: 10 mg daily Ticagrelor: 90mg twice daily Special population Clinical Presentation Anginal pain in NSTE-ACS patients may have the following presentations:
Prolonged (.20 min) anginal pain at rest; New onset (de novo) angina (class II or III of the Canadian Cardiovascular Society classification); Recent destabilization of previously stable angina with at least Canadian Cardiovascular Society Class
III angina characteristics (crescendo angina); or Post-MI angina. Diagnosis 0 h/3 h rule-out algorithm of non-ST-elevation acute coronary syndromes using highsensitivity cardiac troponin assays
New: 0 h/1 h rule-in & rule-out algorithm of non-ST-elevation acute coronary syndromes using high-sensitivity cardiac troponin assays Recommendations Recommendations for antiischaemic drugs in the acute phase Recommendati ons in DAPT
Recommendati ons in DAPT NE W Dosing of glycoprotein IIb/IIIa inhibitors in patients with normal and impaired renal function Dosing of anticoagulants in patients with normal and impaired renal function
Recommendation NE s for W anticoagulation Suggested strategies to reduce bleeding risk related to PCI NE W Antithrombotic strategies in patients
with NSTEMI and non-valvular A. Fib Recommendations for combining antiplatelet agents and anticoagulants in NSTEMI patients requiring chronic oral anticoagulation Risk criteria mandating invasive strategy in NSTE-ACS Selection of treatment strategy and timing according to initial risk stratification.
Recommendations for perioperative management of antiplatelet therapy patients requiring CABG Recommendations for invasive coronary angiography and revascularization
Recommendations for the management of patients with heart failure NSTEMI Recommendations for longterm management after non-ST-elevation acute coronary syndromes To do and not to do messages from the guidelines
Introduction to . Artificial Intelligence (AI) ... The current reality is that computers and some robots can do some really remarkable complex tasks, and in some cases do them better than humans. ... A technique that involves the analysis of...
Biotechnology Timeline. 1983. The polymerase chain reaction (PCR) technique, which makes unlimited copies of genes and gene fragments, is conceived. Kary Mullis, who was born in Lenoir, N.C., wins the 1993 Nobel Prize in Chemistry . for the discovery. He...
Cañada College provides our community with a learning-centered environment, ensuring that all students have equitable opportunities to achieve their transfer, career education, and lifelong learning educational goals. The College cultivates in its students the ability to think critically and creatively,...
Times New Roman Arial Narrow Arial Showcard Gothic MS Mincho Courier New Default Design Water movements Question of the day Surface gravity waves Surface gravity waves Currents (moving water) Eckman spiraling currents Convection (density) currents Langmuir spirals Langmuir spirals Surface...
A means of communicating; specif., a system for sending and receiving messages, as by telephone, telegraph, radio, etc. A system as of routes for moving troops and material. A passage or way for getting from one place to another. The...
Technology base: UV absorbers and whiteners Sensitive Skin Protection Comfort wear for kids Powerfull protection that lasts UPF 50+ tested in accordance to the AS/NZS standard 4399 High IQ® - Sun protection for Kids Benefits for customers Active outdoor protection...
Senator Richard Blumenthal, Democrat of Connecticut, said . Democrats in Congress who have one of the pending lawsuits against Mr. Trump . will now revise it to include the president's plan to have the Group of 7 meeting at the...